G protein-coupled receptors (GPCRs) constitute the largest gene family in the human genome and accumulate the most successful biochemical targets for therapeutic drugs. The natural ligands of about 140 GPCRs are unknown and they are thus called """"""""orphan"""""""" receptors. Identification of these natural ligands forms the crucial step to start studying their function and holds the potential for development of novel pharmaceutical drugs. We have developed a strategy to isolate such natural ligands by expressing the cloned receptors in suitable cell lines and monitoring activation of the receptors after adding fractions of tissue extracts. This novel strategy will ultimately allow us to purify the active molecules and determine their structure. In this application, we propose to apply this highly innovative technique to isolate, identify and characterize the natural ligand of the orphan receptor bombesin subtype-3 (BRS-3) that is still elusive. BRS-3 receptor is expected to play an important role in integrating and modulating the complex physiology underlying feeding as evidenced by the fact that mice devoid of BRS-3 receptor are hyperphagic, hypometabolic and develop an obese phenotype. This receptor does not bind the two known mammalian bombesin counterparts of the frog peptide neuromedin B and gastrin-releasing peptide that bind to the other two bombesin receptor subtypes (BB-1 and 2). Following the isolation of the natural ligand, we will characterize the pharmacological effects, study the Subsequently, we propose to study the BRS-3 ligand in a behavioral feeding assay in order to determine its mode of action. The BRS-3 ligands will prove as an invaluable tool to answer the functional significance and understand the physiological role of the BRS-3 system in the regulation of energy balance.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21MH068396-01
Application #
6670535
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Brady, Linda S
Project Start
2003-07-01
Project End
2005-06-30
Budget Start
2003-07-01
Budget End
2004-06-30
Support Year
1
Fiscal Year
2003
Total Cost
$143,925
Indirect Cost
Name
University of California Irvine
Department
Pharmacology
Type
Schools of Medicine
DUNS #
046705849
City
Irvine
State
CA
Country
United States
Zip Code
92697
Clark, S D; Alderson, H L; Winn, P et al. (2007) Fusion of diphtheria toxin and urotensin II produces a neurotoxin selective for cholinergic neurons in the rat mesopontine tegmentum. J Neurochem 102:112-20
Jackson, Valerie R; Nothacker, Hans-Peter; Civelli, Olivier (2006) GPR39 receptor expression in the mouse brain. Neuroreport 17:813-6
Jackson, Valerie R; Lin, Steven H; Wang, Zhiwei et al. (2006) A study of the rat neuropeptide B/neuropeptide W system using in situ techniques. J Comp Neurol 497:367-83
Nothacker, Hans-Peter; Wang, Zhiwei; Zeng, Hua et al. (2005) Proadrenomedullin N-terminal peptide and cortistatin activation of MrgX2 receptor is based on a common structural motif. Eur J Pharmacol 519:191-3
Huitron-Resendiz, Salvador; Kristensen, Morten P; Sanchez-Alavez, Manuel et al. (2005) Urotensin II modulates rapid eye movement sleep through activation of brainstem cholinergic neurons. J Neurosci 25:5465-74
Nothacker, Hans-Peter; Clark, Stewart (2005) From heart to mind. The urotensin II system and its evolving neurophysiological role. FEBS J 272:5694-702